Updated: Weaker Omicron variant is great news for the world, but bad news for Covid-related clinical trials
As the world cheers over the weaker (but still not quite mild) Omicron variant, with its reduced Covid-related hospitalizations and deaths when compared to the Delta variant, sponsors of clinical trials that depend on new Covid-19 cases to finish their work are being altered or halted because of Omicron.
SAB Therapeutics said early Wednesday that NIH has halted enrollment in its ACTIV-2 Phase III trial for its potential polyclonal antibody due to low Omicron-related hospitalization and death rates “that have made the current study design statistically unworkable.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.